Secukinumab Reduces Endothelial Dysfunction in Subjects With Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study. J of Skin 2018, 2 (S1), S20. https://doi.org/10.25251/skin.2.supp.20.